In 2017, our program became the first in the West to begin using transmagentic stimulation (TMS) and ROSA Brain to provide even more exceptional care to our patients. TMS is a non-invasive outpatient procedure for epilepsy & tumor patients and provides greater accuracy, smaller incisions and reduced OR and MRI time. ROSA Brain also offers improved accuracy and decreased OR time for depth electrode placement, resulting in decreased injuries in endo and navigated procedures.
In 2017, our program became the first in the West to begin using transmagentic stimulation (TMS) and ROSA Brain to provide even more exceptional care to our patients. TMS is a non-invasive outpatient procedure for epilepsy & tumor patients and provides greater accuracy, smaller incisions and reduced OR and MRI time. ROSA Brain also offers improved accuracy and decreased OR time for depth electrode placement, resulting in decreased injuries in endo and navigated procedures.
Together, these technologies use fewer resources, change how we surgically treat drug-resistant epilepsy, decreases patient risk, shortens hospital stays by up to five days and provides safer, lower cost (but higher value) surgical care.